Ozanimod

Systematic (IUPAC) name
	5-(3-{(1S)-1-[(2-Hydroxyethyl)amino]-2,3-dihydro-1H-inden-4-yl}-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile
Clinical data
Legal status	Investigational;
Identifiers
CAS Number	1306760-87-1
PubChem	CID: 52938427
ChemSpider	34979946
Synonyms	RPC1063
Chemical data
Formula	C23H24N4O3
Molecular mass	404.46 g/mol
	SMILES CC(C)Oc1ccc(cc1C#N)c2nc(no2)c3cccc4c3CC[C@@H]4NCCO ;
	InChI InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1 ; Key:XRVDGNKRPOAQTN-FQEVSTJZSA-N ;

Ozanimod is an experimental drug for the treatment of multiple sclerosis and ulcerative colitis.^[1] It is an immunotherapy that modulates the sphingosine-1-phosphate 1 receptor.^[2]

References

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.